Ultragenyx Pharmaceutical | RARE - Net Income


Ultragenyx Pharmaceutical reported $-185M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Acadia Pharmaceuticals USD 3.64M 269.93M Mar/2026
Agios Pharmaceuticals USD -99.11M 8.93M Mar/2026
Alnylam Pharmaceuticals USD 205.99M 19.57M Mar/2026
BioCryst Pharmaceuticals USD 245.84M 232.95M Dec/2025
BioMarin Pharmaceutical USD 105.53M 152.1M Mar/2026
Esperion Therapeutics USD 61.83M 93.16M Dec/2025
Immunic USD -19.3M 6.28M Dec/2025
Insmed USD -163.56M 164.92M Mar/2026
Ionis Pharmaceuticals USD -93M 136M Mar/2026
Karyopharm Therapeutics USD -102.2M 71.42M Dec/2025
Kyowa Hakko Kirin JPY 12.03B 22.41B Mar/2026
MacroGenics USD -14.16M 30.98M Dec/2025
Moderna USD -1.34B 517M Mar/2026
Neurocrine Biosciences USD 197.9M 44.2M Mar/2026
PTC Therapeutics USD -2.81M 132.16M Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 727.2M 117.4M Mar/2026
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
Vertex Pharmaceuticals USD 1.03B 159.7M Mar/2026
Xoma USD -17.24M 33.23M Sep/2024